HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chatal, J.-F. Articles by Koprowski, H. Search for Related Content PubMed PubMed Citation Articles by Chatal, J.-F. Articles by Koprowski, H.

Immunoscintigraphy of Colon Carcinoma

U.211 INSERM and Centre René Gauducheau, U.E.R. de Médecine, 1, 44035 Nantes Cedex, Office des Rayonnements: Ionisants, Saclay, France
The Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania

Correspondence: For reprints contact: Jean-Francois Chatal, Laboratoire de Rechcrche, INSERM U.211, UER de Medecine, I, rue Gaston Veil, 44035 Nantes Cedex, France.

ABSTRACT

Two I-131 labeled monocional antibodies that react specifically with human gastrointestinal cancers in cell cultures were administered to 90 cancer patients for the scintigraphic detection of cancer sites. Antibody 17-1A, or its F(ab')₂ fragments, accumulated significantly in 27 of 46 (59%) colorectal cancer sites, but not in 21 nonepithellomatous colon cancers and cancers at other sites. Antibody 19-9, or its F(ab')₂ fragments, showed significant accumulation in 19 out of 29 (66%) colorectal cancer sites. In 17 patients, immunoscintigraphy with antibody 19-9 correlated with an immunoperoxidase study with the same antibody on resected tissue specimens. In 12 patients injected with two antibodies (17-1A + 19-9, or anti-CEA + 19-9), ten of 13 colorectal cancer sites were positive.